In conclusion, our study demonstrates relevant in vitro and in vivo anti-cancer effects of OCA against human iCCA primary cultures and this reinforces accumulating evidence of FXR as a therapeutic target in patients with CCA. This evidence concerns the gene NR1H4 and cholangiocarcinoma.